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Background: According to the Lauren classification, gastric adenocarcinomas are divided into diffuse and intestinal
types. The causative attribution explaining the dismal prognosis of diffuse-type remains unknown.
Methods: We examined the archive of 1000 patients with gastric adenocarcinomas who received radical
gastrectomy in our center and assessed the effect of the Lauren classification on survival in a multivariate approach.
Moreover we compared the variation of clinical features between the diffuse-type and intestinal-type and explored
the contributing factors for the prognostic difference.
Results: There were 805 resectable patients for the final analysis. Diffuse-type comprised of 48.7% in the gastric
carcinoma in our group and showed poorer prognosis than intestinal-type (P=0.013). Multivariate analysis revealed
that independent prognostic factors for gastric carcinoma patients were T stage (P<0.001), N stage (P<0.001) tumor
size (P<0.001) and Lauren classification (P=0.003). For the clinical features, diffuse-type was significantly associated
with younger age (p<0.001), female preponderance (p <0.001), distal location (P<0.001), advanced pT (p < 0.001),
advanced pN (p < 0.001) and advanced TNM stage (p = 0.027).
Conclusions: Diffuse type adenocarcinoma carries a worse prognosis that may be partially explained by the
tendency of this subtype to present at more advanced T and N stage. However, Lauren classification has prognostic
significance that is independent of T and N stage as well as other prognostic variables based on the multivariate
cox analysis.
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About one million people are diagnosed with gastric
carcinoma each year all over the world, making it the
fourth most common cancer and the second leading
cause of cancer related death [1]. The incidence rate of
gastric carcinoma varies dramatically from one part of
the world to another and it is particularly common in
Eastern Asia, including China [2]. The prognosis for
gastric adenocarcinoma patients remains poor and our
understanding of this cancer entity is still limited.* Correspondence: xurh@sysucc.org.cn
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reproduction in any medium, provided the orAccording to the Lauren classification, gastric adeno-
carcinomas can be divided into two major histological
types, diffuse and intestinal type [3]. The intestinal type
is characterized by cohesive cells which form gland-like
structures, while for the diffuse type, tumor cells lack
cell-to-cell interactions and infiltrate the stroma as sin-
gle cell or small subgroups, leading to a population of
non-cohesive, scattered tumor cells [3]. Although the
Lauren classification system can date back to 1965, it is
still widely accepted and employed by pathologists and
physicians today and represents a simple but robust clas-
sification approach. The two Lauren types have several
distinct clinical and molecular characteristics, including
etiology, carcinogenesis, epidemiology and progression,
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profiles [4]. Thus, it is widely accepted that they repre-
sent distinct disease entities which may benefit from
different therapeutic approaches. In the recent reported
clinical trial—Trastuzumab in combination with chemo-
therapy versus chemotherapy alone for treatment of
HER2-positive advanced gastric or gastro-oesophageal
junction cancer (ToGA), patients in the control group
had a higher overall survival rates than expected [5] and
the authors considered that it might be due to the higher
percentage of intestinal-type tumors in the control
group compared with other phase III studies [6]. It was
reported that the expression of human epidermal growth
factor receptor-2 (HER2) was more common in intestinal-
type tumors and such patients have a better outcome than
patients with diffuse-type tumors [7-10]. The importance
of Lauren classification took our attention.
The aims of our present study are: (1) to analyze the
prognostic value of Lauren classifications in resectable
gastric cancer patients in China, (2) to compare the
clinicopathological characteristics of diffuse-type and
intestinal-type in gastric cancer and identify the clinico-
pathological factors which may explain the different
prognosis of the these two types.
Materials and methods
Ethics statement
All patients provided written informed consent for their
information to be stored and used in the hospital data-
base. Study approval was obtained from independent
ethics committees at Cancer Center of Sun Yat-Sen
University. The study was undertaken in accordance with
the ethical standards of the World Medical Association
Declaration of Helsinki.
Patients
The medical records of 1000 patients with pathologically-
confirmed gastric adenocarcinoma between January 1996
and December 2006 were retrospectively analyzed. They
all received D2 resection carried out by experienced
surgeons in the Cancer Center of Sun Yat-Sen University
following the Japanese Gastric Cancer Association (JGCA)
guidelines [11]. Both the proximal and distal margins are
negative and at least 3 cm away from the tumor. Besides,
the surgeon dissected the station D2 lymph nodes. There
is no macroscopic or microscopic residual tumor. The
total number of dissected lymph nodes of the 1000 gas-
tric carcinoma patients was 16008, with an average of
18.8 ±5.3 (means±s.d.) dissected nodes per case (median
24.0, range 13–72). The number of excised lymph nodes
was less than 15 in 24.2% of patients who received resection.
We excluded 82 patients (8.2%) because of missing
baseline characteristics, 75 patients (7.5%) younger than
18 years old, 32 patients (3.2%) with incomplete follow-up and 6 patients (0.6%) with secondary malignancy.
None of the patients received neoadjuvant treatment.
The final study involved 805 patients.
The clinical features collected for subsequent analysis
included gender (male or female), age at diagnosis (<59
or ≥59 years, the median age was 59), tumor size (≤5 cm
or >5 cm, the median diameter was 5 cm), location of
primary tumor (proximal or distal), histology subtypes
(well + moderate differentiated adenocarcinoma or poorly
+ signet ring cell differentiated adenocarcinoma), Lauren
classifications (diffuse type or intestinal type), anemia (yes
or no), angiolymphatic invasion (yes or no), the TNM sta-
ging system (American Joint Committee on Cancer (AJCC)
7th edition) (Table 1).
During the study period we did not have a standard-
ized protocol for postoperative chemotherapy and (or)
radiotherapy. Adjuvant therapy was considered in pa-
tients with T3-T4 classification and/or positive lymph
node involvement. In the present study, only 532
(66.1%) patients completed the adjuvant chemotherapy
(2–6 cycles). Agents using for chemotherapy included
oxaliplatin, 5-fluorouracil, capecitabine, S-1, irinotecan,
docetaxol and taxol. The median number of cycles was
4. No patients received adjuvant radiotherapy. As of
May 1st, 2012, 403 patients had died from the disease.
Tissue samples from resected tumors were classified
and staged by an experienced pathologist according to
the WHO classification and the TNM staging system
following general pathological guidelines. Assignment of
the histologic type was based on the Lauren criteria. The
intestinal type was described as a tumor with glandular
architecture, resembling colonic carcinoma; the diffuse
type, as a tumor composed of solitary or small clusters
of cells, and lacking glandular structures. The mixed
type was described as the combination of these two
features. Two pathologists reviewed the original diagnos-
tic slides in order to grade, stage and classify the tumors
as intestinal or diffuse type.
Statistical analysis
All statistical analyses were performed by Statistical Pack-
age of Social Sciences 13.0 software. P value < 0.05 was
considered to be statistically significant. The Kaplan-Meier
method was used to estimate overall survival. For patients
who remained alive, data were censored at the date of the
last contact. Kaplan-Meier analysis with log-rank testing
was used for univariate analysis. The definition of the
overall survival interval was the duration between the date
of diagnosis and the date of last contact. Variables showing
a trend for association with survival (P < 0.05) and vari-
ables that were known to have prognostic value were
selected in the final multivariable Cox proportional haz-
ards model, while variables that are highly associated with
others were excluded from the final multivariable model.










≤59 392 246 146
>59 356 150 206
Sex <0.001
Female 298 211 87
Male 450 181 269
Time period 0.041
1996.1–2000.12 118 72 46
2001.1–2006.12 630 320 310
Location of tumor <0.001
Proximal 326 129 197
distal 422 263 159
Size 0.268
≤5 cm 453 230 223
>5 cm 295 162 133
The 7th T stage (AJCC) <0.001
T1 61 24 37
T2 79 55 24
T3 532 260 272
T4 76 57 19
The 7th N stage (AJCC) <0.001
N0 259 112 147
N1 116 52 64
N2 161 92 69
N3 212 140 72
The 7th TNM stage (AJCC) 0.027
I 113 47 66
II 280 146 134
III 355 199 156
Histology subtype <0.001
Well + Moderate 281 0 281
Poor + signet ring cell 467 392 75
Abbreviations: AJCC, American Joint Committee on Cancer; TNM, Tumor-Node-
Metastasis; The analysis only includes 748 patients, and excludes 57 mixed
diffuse-intestinal types.
Table 1 Demographics and univariate survival analysis
results of the 805 gastric carcinoma patients





female 248 46.1 0.581
Age median 59
≤59 419 50.5
>59 386 45.8 0.135
Lauren classification
Diffuse type 392 44.1
Intestinal type 356 52.7 0.013
Tumor size
≤5 cm 483 55.2
>5 cm 322 38.5 <0.001
Anemia
Yes 247 57.4
No 558 61.0 0.554
Angiolymphatic invasion
Yes 52 36.5
No 753 48.8 0.009
Location of tumor
Proximal 347 42.5
Distal 458 49.4 0.017
Number of lymph nodes
<15 195 46.9
≥15 610 51.4 0.233
Type of gastrectomy
Proximal subtotal 323 45.2
Distal subtotal 386 56.9
Total 96 31.5 <0.001




T4 127 27.5 <0.001




N3 232 23.0 <0.001





Table 1 Demographics and univariate survival analysis
results of the 805 gastric carcinoma patients (Continued)
IIIA 82 59.5
IIIB 132 43.7
IIIC 163 24.3 <0.001
Abbreviations: AJCC, American Joint Committee on Cancer; TNM, Tumor-Node-
Metastasis.
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The median age of the 805 patients was 59 years (ranging
from 20 to 84 years old). Among them 557 were male and
248 were female. The overall 5-year survival for the
patient population was 48.2%, with a median survival of
53.4 months. The median follow-up for the entire cohort
was 42.0 months (range 3.0–173.0 months). The charac-
teristics of the 805 gastric adenocarcinoma patients and
the effect of clinical features on survival are summarized
in Table 1.
Lauren classification
There were 396 (49.2%) patients with diffuse-type and
352 (43.7%) patients with intestinal-type carcinoma. The
remaining 57 patients belonged to the mixed-type car-
cinoma. In the following analysis, we only included the
748 patients with the diffuse-type or intestinal-type
carcinoma.
Patient characteristics of the two groups are shown in
Table 2. Among intestinal-type carcinoma, 146 (41.5%)
were younger than 60 years old compared to 246 (62.1%)
of patients with diffuse-type carcinoma (P<0.001). The
ratio of male to female was significantly higher in theFigure 1 Survival curves of gastric adenocarcinoma patients with diffintestinal-type carcinoma group than that in the diffuse-
type group, 3.1 vs 0.86 (P<0.001). We divided the ten year
study period into two groups, the early period: from
January 1996 to December 2000, the later period: from
January 2001 to December 2006. We found that the ratio
between diffuse type to intestinal type decreased from
1.57 (early period) to 1.03 (later period), P=0.041. Among
intestinal-type carcinomas, 55.3% of tumors were located
in the proximal stomach compared to 32.9% of diffuse-
type carcinomas, (P <0.001). The mean size of tumors was
about 51.6 mm for diffuse-type carcinomas and 50.2 mm
for intestinal-type , P=0.268. Distribution of T-stage was
significantly different between the diffuse-type and the
intestinal-type (Table 2). Moreover, for the lymph nodes
status, 41.3% of patients with intestinal-type carcinoma
had no evidence of lymph nodes metastasis, while for the
diffuse-type carcinoma, the rate of N0 was 28.6%. Besides,
the ratio of stage I: II: III was 12.1%:37.2%: 50.7% in the
diffuse-type, nevertheless, it was 18.5%: 37.7%: 43.8% in
the intestinal-type, P=0.027.
Univariate and multivariable analyses of overall survival
Both univariate and multivariable analyses were used to
evaluate factors relating to overall survival. Factors of
Lauren classification, tumor size, angiolymphatic invasion,
location of tumor, degree of differentiation, T stage, N
stage and TNM stage in the AJCC 7th system wereuse-type and intestinal-type.
Table 3 Multivariate analysis of overall survival in gastric carcinoma
Factors Characteristics Hazard ratio 95%CI P value
Unfavorable Favorable
Age ≥59 <59 1.111 0.899–1.374 0.328
Gender Female Male 1.057 0.843–1.324 0.631
Lauren classification Diffuse type Intestinal type 0.736 0.595–0.910 0.005
Histological grade Poorly Well/moderately 1.025 0.899–1.167 0.714
Size >5 cm ≤5 cm 1.605 1.307–1.972 <0.001
Location Proximal Distal 0.852 0.697–1.042 0.120
T stage 2/3/4 1 1.890 1.230–2.746 <0.001
N stage 1/2/3 0 1.368 1.048–1.894 <0.001
Angiolymphatic invasion (+) (−) 1.209 0.831–1.759 0.321
Type of gastrectomy Total Subtotal 1.135 0.859–1.468 0.582
CI, confidence interval.
Table 4 Ratio of the diffuse type to intestinal type of








Our data 396 352 57 1.13
Hawaii Japanese 16 144 109 41 1.32
Singapore 21 206 405 37 0.51
Portugal 22 48 112 12 0.43
Finland 25 537 729 177 0.74
* Ratio means the ratio of the diffuse type to intestinal type gastric carcinoma.
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5-year overall survival rate of patients with diffuse-type
and intestinal type were 44.1% and 52.7%, respectively,
P=0.013 (Figure 1).
For the multivariable regression analysis, only T stage
(P<0.001), N stage (P<0.001),tumor size (P<0.001) and
Lauren classification (P=0.003) remained independent
negative predictors of survival (Table 3).
Discussion
In 1965, Lauren proposed a division of gastric carcinoma
into two structurally distinct types, the intestinal-type
and the diffuse-type [3]. The former was most frequently
seen in men and older patients and the latter had a
worse prognosis and was more frequent in women and
younger patients. He proposed that these two types
could account for approximately 85% of gastric carcin-
omas, and the remainder comprised mixed types and
other less common histologies. Several studies have
found that the Lauren classification is reproducible
[12-16]. Our study confirmed the fact that patients with
the diffuse-type of gastric carcinoma had poorer prog-
nosis than patients with intestinal type (P = 0.013) in
our Chinese patient population. Multivariate analysis
revealed that independent prognostic factors for patients
with resected gastric adenocarcinoma were TNM stage,
tumor size and the Lauren classification. Our previous
studies also showed that tumor size was an independent
negative predictor of survival in lymph nodes negative
gastric carcinoma patients [17]. While the histology was
eliminated. Several studies have indicated that patients
with intestinal-type tumors had a better outcome than
those with diffuse-type tumors [8-10]. The two Lauren
types varied in several clinical and molecular characteris-
tics. We tried to seek the difference between these two
types in the clinical features which may be responsible
for the survival variation.In our study, diffuse-type gastric carcinoma was sig-
nificantly associated with younger age (p <0.001), female
preponderance (p <0.001), distal location (P<0.001),
advanced pT (p < 0.001), advanced pN (p < 0.001) and
advanced TNM stage (p = 0.027). Though the impact of
age, gender and location as prognostic factors was still
controversial, it is well accepted that advanced pN as
well as advanced pT are poor prognostic factors for
gastric carcinoma [17-20]. The higher percentage of
patients with advanced pN and advanced pT subtypes in
the diffuse-type gastric carcinoma as compared with the
intestinal-type may contribute to the poor prognosis of
patients with diffuse-type. Yamashita K et al. revealed
that the more dismal prognosis of diffuse-type gastric
carcinoma than intestinal-type could be explained by
propensity of deeper invasion and emerging peritoneal
cancer cell in the Japanese population [8]. In our study,
we demonstrated that high percentage of advanced pN
was also responsible for the poor prognosis of diffuse-type
in Chinese patients with resectable gastric carcinoma.
The present study shows that both diffuse-type and
intestinal-type carcinoma account for 92.9% (748/805) of
gastric carcinoma in China. Diffuse-type accounted for
48.7% (392/805) of all gastric carcinomas. It was reported
that intestinal type was more common in areas with a
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relatively more common in low-risk areas [13]. The ratio
of diffuse and intestinal types of gastric carcinoma in
China (1.13) was similar to the Hawaii Japanese popula-
tion, which was 1.32, while in European countries, such as
Finland and Portugal, intestinal type was more common
(Table 4) [13,16,21,22].
In our study we found that the intestinal-type was
more frequently in males and in elderly patients, while
the diffuse-type occurred more frequently in women and
young patients. This results confirms the observations of
others [12-15]. The 3.6 ma1e:female ratio for the intes-
tinal type and 0.86 ratio for diffuse tumors in our study
is comparable to that noted in Fukuoka, Japan , where
they were 2.60 and 0.5 respectively [23], and in Hawaii
Japanese, where these ratio were 2.39 and 0.86 respect-
ively [18].
In China, not all the patients would go to the same
hospital during the course of treatment, maybe after
recurrence they would transfer to the local hospital or
quit treatment. We tried to get the data of recurrence but
some of the patients forgot the date of recurrence. That is
why we don’t analyze the recurrence free survival.
In our previous study, we showed that as the age
increased there was a steady increasing in the proportion
of male and steady decreasing of female [24]. Similarly,
we presently also found a steady increasing in the ratio
between male and female as the age increased. This
suggests a positive relationship between the age and the
male: female ratio, however the exact nature of the
correlation between gender, age and Lauren classifica-
tions warrants further study.
In our study, we found a decrease in the ratio between
diffuse type to intestinal type over time from 1.57 (from
January 1996 to December 2000) to 1.03 (from January
2001 to December 2006), P=0.041. However, Pekka A
et al. found that in a Finland based population,the ratio of
diffuse-type to intestinal-type increased over time sugges-
ting differences in the epidemiologic shift of gastric carcin-
omas between Eastern and Western populations [25].
The limitation of current study is its retrospective
methodology from a single-institution experience. The
impact of various treatments related outcome could not
be fully evaluated. Moreover, it is inaccurate to analyze
the recurrence free interval. External validation by using
other large database for evaluating the prognostic effect
of Lauren classification would be of value to further
explore the mechanism of different prognosis between
diffuse-type and intestinal-type gastric carcinoma.
Conclusion
The authors are not aware of any previous studies which
address the clinicopathological characteristics and prog-
nostic impact of the Lauren classification in patients withresectable gastric cancer in China. In this retrospective
study conducted with 805 patients with gastric adenocar-
cinoma we submit the following conclusions: 1) The
combination of TNM staging with Lauren classification
and tumor size are the most meaningful prognostic
factors. 2) Advanced pN as well as advanced pT appear to
account for the poor prognosis of diffuse-type in Chinese
patients with resectable gastric carcinoma.
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